文献速递外周动脉疾病

SuperB与Zilverpass试验的事后分析:长段复杂股浅动脉病变的治疗

Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions.
PubMed 文献 · J Vasc Surg · 2024-04-09

该研究事后合并SuperB与Zilverpass试验的血管内治疗组数据,比较肝素涂层自膨式覆膜支架(Viabahn,SECS)与药物洗脱支架(ZilverPTX,DES)治疗长段复杂股腘动脉病变的1年结局。共纳入176例(SECS组63例,DES组113例),两组1年一期通畅率无显著差异,仅符合方案分析中DES组二期通畅率显著更优,支持对长段复杂股腘动脉病变行血管内治疗。

要点

  • 1年一期通畅率SECS组与DES组无显著差异(意向性分析63.4% vs 71.1%,P=.183)。
  • 符合方案分析中二期通畅率DES组显著优于SECS组(95.1% vs 85.6%,P=.038)。
  • 两组免于靶病变血运重建率无显著差异(79.6% vs 77.0%,P=.481)。

核心结论

  • 肝素涂层Viabahn覆膜支架与ZilverPTX药物洗脱支架治疗复杂股腘动脉病变的1年一期通畅率、二期通畅率及靶病变血运重建率相似,但符合方案分析中二期通畅率DES组更优。
  • 该研究进一步支持对股腘动脉长段复杂病变行血管内治疗。

研究设计与样本

  • SuperB试验与Zilverpass试验的事后分析,合并两试验数据库,纳入血管内治疗组患者。
  • 共纳入176例患者,SECS组63例,DES组113例,按意向性治疗和符合方案两种方式分析。
  • 主要终点为1年随访时的一期通畅率,次要终点为二期通畅率、靶病变血运重建、肢体丢失和全因死亡。

主要发现

  • 1年一期通畅率意向性分析SECS组63.4% vs DES组71.1%(P=.183),符合方案分析SECS组60.8% vs DES组71.1%(P=.100),均无显著差异。
  • 1年二期通畅率意向性分析SECS组86.5% vs DES组95.1%(P=.054),无显著差异;符合方案分析SECS组85.6% vs DES组95.1%(P=.038),DES组显著更优。
  • 免于靶病变血运重建率SECS组79.6% vs DES组77.0%(P=.481),无显著差异。
  • SECS组无大截肢,DES组大截肢2例(1.8%);1年生存率SECS组98.2% vs DES组91.3%(P=.106)。
  • 按诊断(间歇性跛行 vs 慢性肢体威胁性缺血)分层,一期通畅率、二期通畅率和免于靶病变血运重建率均无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In two randomized controlled trials, the outcomes of endovascular treatment of complex femoropopliteal arterial lesions were compared with bypass surgery and considered a valid alternative treatment. The aim of this study was to compare both endovascular treatment options with the hypothesis that implantation of heparin-bonded self-expanding covered stents (Viabahn [SECS]) or drug-eluting stents (ZilverPTX [DES]) are related to similar clinical outcomes at 1-year follow-up. METHODS: In a post-hoc analysis, the SuperB trial and Zilverpass databases were merged. Patients in the endovascular treatment arms were included, and data was analyzed in an intention-to-treat (ITT) and a per-protocol (PP) fashion. Data included baseline and lesion characteristics, procedural details, and follow-up data. The primary endpoint of this study was primary patency at 1-year follow-up. The secondary endpoints were secondary patency, target lesion revascularization (TLR), limb loss, and all-cause mortality. RESULTS: A total of 176 patients were included; 63 in the SECS arm and 113 in the DES arm. Through 1-year follow-up, there were no significant differences in primary patency (ITT: 63.4% vs 71.1%: P = .183 and PP: 60.8% vs 71.1%; P = .100). Secondary patency rates were not significantly different in the ITT analysis (86.5% vs 95.1%; P = .054), but in the PP analysis, there was a significant difference in favor of the DES group (SECS, 85.6% vs DES, 95.1%; P = .038). There was no significant difference in freedom from TLR between groups (79.6% vs 77.0%; P = .481). No major amputations were performed in the SECS group, and two were performed in the DES group (1.8%). Survival rate was 98.2% in the SECS group, and 91.3% in the DES group after 1-year follow-up (P = .106). Based on diagnosis (intermittent claudication vs chronic limb-threatening ischemia) no differences between patients with intermittent claudication and chronic limb-threatening ischemia were observed in primary patency, secondary patency and freedom from TLR. CONCLUSIONS: Treatment of complex femoropopliteal arterial disease with the heparin-bonded Viabahn endoprosthesis and the Zilver PTX drug-eluting stent are related to similar primary and secondary patency, and TLR rates at 1 year, except for secondary patency in the PP analysis. This study further supports the endovascular treatment of long complex lesions in the femoropopliteal artery.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. van Walraven LA, Kalil VM, van der Veen D, et al. Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions. J Vasc Surg. 2024. PMID: 38604319. doi:10.1016/j.jvs.2024.03.449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。